PDCD1 and neoplasm: Encouragingly, the results demonstrated that V‐9302 not only inhibited tumor growth in CSCC organoids but also sensitized 3D T‐cell‐incorporated CSCC organoids to anti‐PD‐1 therapy (Figure 7E,F).